Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Recent Posts
ACCENT Trial Update
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Archives
March 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
Categories
Company News
Media
Uncategorized
Videos
August 18th, 2022
The Front Podcast | 18 August 2022
Read More
August 18th, 2022
MEDIA RELEASE | Australian-made treatment for pancreatic cancer – clinical trial milestone
Read More
August 2nd, 2022
First patient recruited into ACCENT trial
Read More
July 28th, 2022
QUARTERLY REPORT & 4C
Read More
June 29th, 2022
The science of manufacturing, at scale
Read More
June 23rd, 2022
Navigating human research ethics
Read More
May 9th, 2022
ABC News | Bioshares
Read More
April 19th, 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
April 7th, 2022
VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial
Read More
April 5th, 2022
New investment in pancreatic cancer research
Read More
March 30th, 2022
Amplia is hiring
Read More
March 17th, 2022
Scientific rigour is in our DNA
Read More
February 17th, 2022
Improving Pancreatic Cancer Survival Rates
Read More
February 11th, 2022
WOMEN IN SCIENCE | Rhiannon Jones, Director, Operations
Read More
February 1st, 2022
VIDEO | PROACTIVE Amplia Therapeutics readies for phase two clinical trials and "watershed year" for AMP945
Read More
January 24th, 2022
Quarterly Report & 4C
Read More
December 2nd, 2021
$2.1M R&D Cash Flow Loan
Read More
November 30th, 2021
VIDEO | SMALL CAPS Amplia Therapeutics makes headway in anti-cancer clinical trial
Read More
November 18th, 2021
VIDEO | PROACTIVE Amplia Therapeutics details summary results from its phase 1 clinical trial of AMP945
Read More
November 17th, 2021
New Phase 1 Clinical Trial Data
Read More
1
2
3
4
5